Response to Immune Checkpoint Inhibition in Two Patients with Alveolar Soft-Part Sarcoma
Jeremy Lewin(Mount Sinai Hospital), Albiruni R. Abdul Razak(Mount Sinai Hospital), Uri Tabori(Hospital for Sick Children), Adam Shlien, Jacalyn Kelly(Hospital for Sick Children), Marcus O. Butler(University of Toronto), Samer Salah(Roche (Switzerland)), Brendan C. Dickson(Mount Sinai Hospital), Nathaniel D. Anderson(Wellcome Sanger Institute), Kyaw Aung(Baptist Health South Florida), Beatrice Y. Lau(Mount Sinai Hospital), Scott Davidson(Hospital for Sick Children)
Cited by 53
Related Papers
Clinical and biological implications of driver mutations in myelodysplastic syndromes
|Blood|2013|1.8k
The Life History of 21 Breast Cancers
|Cell|2012|1.5k
Somatic<i>SF3B1</i>Mutation in Myelodysplasia with Ring Sideroblasts
|New England Journal of Medicine|2011|1.2k
Overall Survival Benefit with Tebentafusp in Metastatic Uveal Melanoma
|New England Journal of Medicine|2021|869